Health utility scores of colorectal cancer based on societal preference in Japan
- 287 Downloads
We measured health utility scores of colorectal cancer (CRC) patients from a societal perspective in Japan.
Twenty-five states of health were described: four metastatic states without severe adverse events (AEs), 16 metastatic states with Grade 3/4 AEs, four adjuvant states, and one terminal state. A total of 1,500 respondents stratified by age and gender were recruited randomly from the largest Web-panel in Japan. Respondents were allocated randomly to three of the 25 health states and answered questionnaires by standard gamble (SG) and time trade-off (TTO) methods.
Although utility scores of metastatic CRC receiving XELOX (capecitabine plus oxaliplatin) chemotherapy were 0.48(SG and TTO) (with stoma) and 0.57(SG) or 0.59(TTO) (without stoma), utility scores of those receiving FOLFOX4 (5-fluorouracil/folinic acid and oxaliplatin) chemotherapy were 0.42(SG) or 0.43(TTO) (with stoma) and 0.52(SG) or 0.53(TTO) (without stoma). These differences between XELOX and FOLFOX4 were statistically significant (P = 0.0198 in SG and P = 0.0059 in TTO). Stage 3/4 AEs decreased utility scores to 0.35–0.4 and 0.4–0.45 in the presence and absence of stoma, respectively.
XELOX was generally considered a significantly preferable chemotherapy regimen compared to FOLFOX4 for CRC in Japan. Almost all Grade 3/4 AEs and stoma significantly decreased utility scores. These differences are dependent on the accuracy of the health state description and to confirm these results. In future research, it would be preferable that preference-based HRQoL measures are used directly in patients if utility scores are practically measurable by such method.
KeywordsColorectal neoplasms Quality-adjusted life-years FOLFOX XELOX Standard gamble Time trade-off
Metastatic colorectal cancer
5-Fluorouracil/folinic acid and oxaliplatin
Capecitabine (Xeloda®) plus oxaliplatin
- 1.Ministry of Health, Labor and Welfare. (2007). Population Survey Report [in Japanese].Google Scholar
- 2.Center for Cancer Control and Information Services, National Cancer Center, Japan. (2007). Regional Cancer Records and Estimated National Figures [in Japanese].Google Scholar
- 5.Douillard, J. Y., Cunningham, D., Roth, A. D., Navarro, M., James, R. D., et al. (2000). Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet, 355(9209), 1041–1047.PubMedCrossRefGoogle Scholar
- 8.Porschen, R., Arkenau, H. T., Kubicka, S., Greil, R., Seufferlein, T., et al. (2007). Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: A final report of the AIO colorectal study group. Journal of Clinical Oncology, 25(27), 4217–4223.PubMedCrossRefGoogle Scholar
- 9.Diaz-Rubio, E., Tabernero, J., Gomez-Espana, A., Massuti, B., Sastre, J., et al. (2007). Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: Final report of the Spanish cooperative group for the treatment of digestive tumors trial. Journal of Clinical Oncology, 25(27), 4224–4230.PubMedCrossRefGoogle Scholar
- 10.Cassidy, J., Clarke, S., Diaz-Rubio, E., Scheithauer, W., Figer, A., et al. (2008). Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. Journal of Clinical Oncology, 26(12), 2006–2012.PubMedCrossRefGoogle Scholar
- 11.Saltz, L. B., Clarke, S., Diaz-Rubio, E., Scheithauer, W., Figer, A., et al. (2008). Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. Journal of Clinical Oncology, 26(12), 2013–2019.PubMedCrossRefGoogle Scholar
- 12.Rothenberg, M. L., Cox, J. V., Butts, C., Navarro, M., Bang, Y. J., et al. (2008). Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: A randomized phase III noninferiority study. Annals of Oncology, 19(10), 1720–1726.PubMedCrossRefGoogle Scholar
- 19.Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365–376.PubMedCrossRefGoogle Scholar
- 27.Gold, M., Siegel, J., Russell, L., & Weinstein, M. (1996). Cost-effectiveness in health and medicine. Oxford: Oxford University Press.Google Scholar
- 28.Ministry of Education, Culture, Sports, Science and Technology. (2008). Labor force survey [in Japanese].Google Scholar